Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple‐Class‐Exposed Relapsed/Refractory Multiple Myeloma

Documenti analoghi

• Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma
  di: Taku Kikuchi, et al.
  Pubblicazione: (2025)
• Elranatamab Exposure–Safety Analysis in Relapsed or Refractory Multiple Myeloma
  di: Pooneh Soltantabar, et al.
  Pubblicazione: (2025)
• Integrating MBMA and QSP to Identify Key Covariates and Predict Treatment Outcomes in Relapsed/Refractory Multiple Myeloma
  di: Zeel Shah, et al.
  Pubblicazione: (2025)
• Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell Lymphoma
  di: Hiroyuki Inoue, et al.
  Pubblicazione: (2025)
• Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta‐Analysis
  di: Pooneh Soltantabar, et al.
  Pubblicazione: (2024)